{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:11:58Z","timestamp":1787238718536,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited data on health-related quality of life (HRQoL) in older breast cancer (BC) patients. This study examines patient-reported outcomes (PROs) by type of endocrine therapy (ET) prescribed, aromatase inhibitors (AI), or tamoxifen (Tam) to estrogen receptor-positive BC patients aged \u226570 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective review includes 1052 women diagnosed with early-stage BC from the REQUITE study database, who underwent breast conservation surgery (BCS), and received adjuvant breast radiation therapy (RT), and ET as the only systemic therapy. Among them, 201 women were aged \u226570 years. The PROs were assessed by using EORTC-QLQ-C30, BR23, and Multidimensional Fatigue Inventory measures obtained at baseline after BCS, post-RT, and at 1, 2, and 3 years follow-up. Statistical analysis involves mixed model analysis of variance and propensity score weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 201 women, 131 received AI, and 70 received Tam. The overall mean age of this cohort is 75.3 years. Compared with Tam, AI-treated patients experience worse insomnia and general and physical fatigue. Tam-treated patients experienced more physical and cognitive functioning decline than the AI-treated patients. The Tam-treated patients also reported more mental fatigue and reduced sexual enjoyment compared to the AI-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests a differential impact by type of ET on distinct HRQoL domains experienced by older postmenopausal women. Furthermore, larger prospective clinical trials are necessary to inform treatment decisions for older ER-positive BC patients, considering patient preferences and understanding trade-offs between disease outcomes and HRQoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-024-16482-4","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T15:46:02Z","timestamp":1745682362000},"page":"4815-4828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Differential Effects of Endocrine Therapy Type on Quality of Life in Older (\u226570 Years) Women with Early-Stage Breast Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Keva","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S.","family":"Rosenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjeet","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"REQUITE Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"5","key":"16482_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/0002-9610(78)90131-9","volume":"135","author":"HJ Kesseler","year":"1978","unstructured":"Kesseler HJ, Seton JZ. The treatment of operable breast cancer in the elderly female. Am J Surg. 1978;135(5):664\u20136. https:\/\/doi.org\/10.1016\/0002-9610(78)90131-9.","journal-title":"Am J Surg"},{"issue":"6319","key":"16482_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/bmj.284.6319.869-a","volume":"284","author":"PE Preece","year":"1982","unstructured":"Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J Clin Res Ed. 1982;284(6319):869\u201370. https:\/\/doi.org\/10.1136\/bmj.284.6319.869-a.","journal-title":"Br Med J Clin Res Ed"},{"key":"16482_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdt284","volume":"24","author":"E Senkus","year":"2013","unstructured":"Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2013;24:7\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdt284.","journal-title":"Ann Oncol."},{"issue":"5","key":"16482_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019;37(5):423\u201338. https:\/\/doi.org\/10.1200\/JCO.18.01160.","journal-title":"J Clin Oncol."},{"issue":"5","key":"16482_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/1055-9965.EPI-20-1193","volume":"30","author":"SC Houghton","year":"2021","unstructured":"Houghton SC, Hankinson SE. Cancer progress and priorities: Breast cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2021;30(5):822\u201344. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-1193.","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol."},{"key":"16482_CR6","unstructured":"SEER*Explorer Application. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=55&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=157&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=1&advopt_show_apc=on&advopt_display=2#resultsRegion1. Accessed January 2, 2024."},{"issue":"1","key":"16482_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3322\/caac.21203","volume":"64","author":"C DeSantis","year":"2014","unstructured":"DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52\u201362. https:\/\/doi.org\/10.3322\/caac.21203.","journal-title":"CA Cancer J Clin."},{"key":"16482_CR8","unstructured":"Cancer of the Breast (Female) - Cancer Stat Facts. SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed January 2, 2024."},{"issue":"1","key":"16482_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2008.08.001","volume":"35","author":"L Balducci","year":"2009","unstructured":"Balducci L. Treating elderly patients with hormone sensitive breast cancer: What do the data show? Cancer Treat Rev. 2009;35(1):47\u201356. https:\/\/doi.org\/10.1016\/j.ctrv.2008.08.001.","journal-title":"Cancer Treat Rev."},{"issue":"12","key":"16482_CR10","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1200\/JCO.2007.14.0459","volume":"26","author":"D Crivellari","year":"2008","unstructured":"Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1\u201398 Trial. J Clin Oncol. 2008;26(12):1972\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.14.0459.","journal-title":"J Clin Oncol."},{"issue":"2","key":"16482_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10549-008-9930-7","volume":"113","author":"J Mathew","year":"2009","unstructured":"Mathew J, Agrawal A, Asgeirsson KS, et al. Primary endocrine therapy in locally advanced breast cancers\u2014the Nottingham experience. Breast Cancer Res Treat. 2009;113(2):403\u20137. https:\/\/doi.org\/10.1007\/s10549-008-9930-7.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"16482_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10549-015-3647-1","volume":"154","author":"RT Chlebowski","year":"2015","unstructured":"Chlebowski RT, Haque R, Hedlin H, et al. Benefit\/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race\/ethnicity. Breast Cancer Res Treat. 2015;154(3):609\u201316. https:\/\/doi.org\/10.1007\/s10549-015-3647-1.","journal-title":"Breast Cancer Res Treat."},{"key":"16482_CR13","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet Lond Engl. 2011;378(9793):771-84. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8","DOI":"10.1016\/S0140-6736(11)60993-8"},{"issue":"11","key":"16482_CR14","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1007\/s00198-010-1493-x","volume":"22","author":"JM Neuner","year":"2011","unstructured":"Neuner JM, Yen TW, Sparapani RA, et al. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int. 2011;22(11):2847\u201355. https:\/\/doi.org\/10.1007\/s00198-010-1493-x.","journal-title":"Osteoporos Int."},{"issue":"27","key":"16482_CR15","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","volume":"341","author":"LF Hutchins","year":"1999","unstructured":"Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. N Engl J Med. 1999;341(27):2061\u20137. https:\/\/doi.org\/10.1056\/NEJM199912303412706.","journal-title":"N Engl J Med."},{"issue":"8","key":"16482_CR16","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/1097-0142(20001015)89:8<1739::AID-CNCR14>3.0.CO;2-F","volume":"89","author":"TL Lash","year":"2000","unstructured":"Lash TL, Silliman RA, Guadagnoli E, Mor V. The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer. 2000;89(8):1739\u201347. https:\/\/doi.org\/10.1002\/1097-0142(20001015)89:8%3c1739::AID-CNCR14%3e3.0.CO;2-F.","journal-title":"Cancer."},{"issue":"3","key":"16482_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","volume":"100","author":"D Cella","year":"2006","unstructured":"Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (\u201cArimidex\u201d, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100(3):273\u201384. https:\/\/doi.org\/10.1007\/s10549-006-9260-6.","journal-title":"Breast Cancer Res Treat."},{"issue":"21","key":"16482_CR18","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","volume":"22","author":"L Fallowfield","year":"2004","unstructured":"Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol. 2004;22(21):4261\u201371. https:\/\/doi.org\/10.1200\/JCO.2004.08.029.","journal-title":"J Clin Oncol."},{"issue":"2","key":"16482_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/sj.bjc.6603258","volume":"95","author":"G Francini","year":"2006","unstructured":"Francini G, Petrioli R, Montagnani A, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006;95(2):153\u20138. https:\/\/doi.org\/10.1038\/sj.bjc.6603258.","journal-title":"Br J Cancer."},{"issue":"1","key":"16482_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10549-011-1400-y","volume":"127","author":"S Ohsumi","year":"2011","unstructured":"Ohsumi S, Shimozuma K, Ohashi Y, et al. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1\u20134 years: N-SAS BC 03. Breast Cancer Res Treat. 2011;127(1):143\u201352. https:\/\/doi.org\/10.1007\/s10549-011-1400-y.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"16482_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-011-1943-y","volume":"133","author":"H Takei","year":"2012","unstructured":"Takei H, Ohsumi S, Shimozuma K, et al. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat. 2012;133(1):227\u201336. https:\/\/doi.org\/10.1007\/s10549-011-1943-y.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"16482_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-012-2028-2","volume":"134","author":"JGH van Nes","year":"2012","unstructured":"van Nes JGH, Fontein DBY, Hille ETM, et al. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat. 2012;134(1):267\u201376. https:\/\/doi.org\/10.1007\/s10549-012-2028-2.","journal-title":"Breast Cancer Res Treat."},{"key":"16482_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.radonc.2019.04.034","volume":"138","author":"P Seibold","year":"2019","unstructured":"Seibold P, Webb A, Aguado-Barrera ME, et al. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol J. 2019;138:59\u201367. https:\/\/doi.org\/10.1016\/j.radonc.2019.04.034.","journal-title":"Radiother Oncol J."},{"key":"16482_CR24","doi-asserted-by":"publisher","unstructured":"The ATAC (Arimidex TA or in CTG. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer. 2003;98(9):1802-10. https:\/\/doi.org\/10.1002\/cncr.11745","DOI":"10.1002\/cncr.11745"},{"issue":"5","key":"16482_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1634\/theoncologist.2015-0349","volume":"21","author":"KC Kadakia","year":"2016","unstructured":"Kadakia KC, Snyder CF, Kidwell KM, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016;21(5):539\u201346. https:\/\/doi.org\/10.1634\/theoncologist.2015-0349.","journal-title":"Oncologist."},{"issue":"1","key":"16482_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-019-05289-7","volume":"177","author":"M Pineda-Moncus\u00ed","year":"2019","unstructured":"Pineda-Moncus\u00ed M, Servitja S, Tusquets I, et al. Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study. Breast Cancer Res Treat. 2019;177(1):53\u201360. https:\/\/doi.org\/10.1007\/s10549-019-05289-7.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16482-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16482-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16482-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:57:38Z","timestamp":1748854658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16482-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["16482"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16482-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"8 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The study was approved by ethics committees in all participating countries (UK NRES Approval 14\/NW\/0035) and registered at\n                      \n                      (ISRCTN98496463).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}